Disclaimer: You are now leaving www.HIVReagentProgram.org and are going to a website that is not operated by NIH HIV Reagent Program. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE:
NIH HIV Reagent Program offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the NIH HIV Reagent Program website and will be redirected to another site. These sites are not under the control of NIH HIV Reagent Program.
NIH HIV Reagent Program is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Please read third party privacy and security policies closely as these may be different than NIH HIV Reagent Program policies.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
colder, preferably in the vapor phase of a liquid nitrogen freezer
Quantity limit per order for this item is 1. This item can be
ordered twice a year. Orders over this limit will be sent to NIAID for approval
ARP-135 is an AK- dCK- subclone of the AA cell line derived from the WIL-2 human splenic Epstein-Barr virus-positive (EBV+) B lymphoblastoid cell line. WIL-2 was originally isolated from the spleen of a Caucasian male with hereditary spherocytic anemia. AA-2 cells were isolated by stepwise selection in 6-methylmercaptopurine ribonuclease and arabinosylcytosine to obtain a clone with <1-3% wild type AK and dCK activity. ARP-135 expresses high levels of CD4 and binds more gp120 than other WIL-2 derivatives.
ARP-135 is remarkably permissive for HIV-1 infection, extremely sensitive to virus cytopathic effects, and is useful for producing high-titer virus stock.
Growth Characteristics: ARP-135 is a lymphoblast-like cell line that grows in suspension in clumps, which are difficult to disperse. Stock cultures are passaged once a week with cells diluted to approximately 1 × 105 per mL. Active cultures should be maintained between 2 × 105 cells per mL and 8 × 105 cells per mL. At this concentration range the cells should double every 24 hours.
Growth Medium: RPMI 1640 medium supplemented with 10% fetal bovine serum, non-essential amino acids and 1 mM sodium pyruvate
ARP-135 is negative for bacteria, Mycoplasma and
Each vial of ARP-135 contains
approximately 4 × 106 cells in RPMI 1640 supplemented with 10% fetal bovine serum, 10% horse serum and 12.5% dimethyl sulfoxide (DMSO). Please refer to the
attached file(s) for additional information.
Chaffee, S., et al. “Phenotypic Variation in the Response
to the Human Immunodeficiency Virus among Derivatives of the CEM T and WIL-2 B Cell
Lines.”J. Exp. Med. 168 (1988): 605-621.
When applying for permits and forms please:
Do NOT reference NIH HIV Reagent Program or ATCC Catalog Numbers in the Material Description
fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly
as they appear on your NIH HIV Reagent Program registration.
Information about permits is provided as a courtesy to NIH HIV Reagent Program customers.
While we use reasonable efforts to include accurate and up-to-date information on
this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the
biological materials provided by NIH HIV Reagent Program, please select this link: Compliance Requirements.
Knowledge Base (FAQs)
Microsoft PowerPoint Viewer
Microsoft Word Viewer
Microsoft Excel Viewer
Call Us Toll-Free:+1 (888) 487-0727
TTY: (703) 365 - 2727